multiple myeloma

Following FDA approval last October, Adaptive has now secured Medicare coverage for its NGS-based minimal residual disease assay, ClonoSeq.

Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.

In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.

These and previously uncovered multiple myeloma risk loci may influence disease by affecting developmental transcriptional regulators.

The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.

The researchers found that both coding and non-coding alterations drive the early development of multiple myeloma.